
Venturis Therapeutics, Inc, Announces Agreement with Pradaxis, Inc for Development of New Therapeutic Indications

Dallas, TX May 18, 2026 - Venturis Therapeutics, Inc (“VT” or the “Company”) has entered into an agreement with a private company, Pradaxis, Inc, to develop additional therapeutic indications using Venturis Therapeutic’s API. The agreement has milestone payments to Venturis based on the progress that Pradaxis makes in each therapeutic area.

“Pradaxis developing additional indications using the advanced science at Venturis will help both companies prove the safety and efficacy of our protein therapy and its use in unmet medical needs. With this partnership, we hope to provide relief to many patients across the world with revolutionary medical care,” stated Calvin Wallen III, CEO, Chairman, and President of VT.

###

ABOUT VENTURIS THERAPEUTICS

VENTURIS THERAPEUTICS, INC. IS A BIOPHARMACEUTICAL COMPANY DEVELOPING PROTEIN DRUG CANDIDATES TO ADDRESS DISEASES SUCH AS DIABETIC WOUNDS, SEVERE CORONARY HEART DISEASE, PERIPHERAL ARTERY DISEASE, ERECTILE DYSFUNCTION, STROKE, PARKINSON’S DISEASE AND SPINAL DISK DISEASE. THE ACTIVE PHARMACEUTICAL INGREDIENT (API) IN OUR DRUG CANDIDATES IS FGF-1, A HUMAN PROTEIN THAT STIMULATES THE GROWTH OF NEW BLOOD VESSELS, THEREBY INCREASING THE BLOOD SUPPLY TO ISCHEMIC ORGANS AND TISSUES